Community Oncology Alliance
Advocating for community oncology practices
Based in VA
🤖
AI Overview
With $2.8M in lobbying spend across 35 quarterly filings, Community Oncology Alliance is a significant lobbying presence. They deploy 12 individual lobbyists
$2.8M
Total Lobbying Spend
35
Quarterly Filings
1
Lobbying Firms Used
12
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2018 | $320K |
| 2019 | $800K |
| 2020 | $80K |
| 2021 | $400K |
| 2022 | $240K |
| 2023 | $320K |
| 2024 | $320K |
| 2025 | $320K |
Lobbying Firms
FARRAGUT PARTNERS LLP
What They Lobby For
- Issues related to pharmacy benefit managers.
- Issues relating to VA claw back on reimbursements for community providers
- Issues pertaining to Medicare reimbursement. Issues pertaining to drug shortages, monitoring legislation regarding the 340B Drug discount program. Issues pertaining to sequestration; H.R. 1934 Cancer Care Payment Reform Act. Issues related to pharmacy benefit managers. HR 1920 Prompt Pay legislation.
- Issues pertaining to Medicare reimbursement. Issues pertaining to drug shortages, monitoring legislation regarding the 340B Drug discount program. Issues pertaining to sequestration; H.R. 1934 Cancer Care Payment Reform Act. Issues related to pharmacy benefit managers.
- Issues pertaining to Medicare reimbursement. monitoring legislation regarding the 340B Drug discount program. Issues pertaining to sequestration; Issues related to pharmacy benefit managers. Drug pricing legislation- ASP reform proposals.
- Issues pertaining to Medicare reimbursement. Issues pertaining to drug shortages, monitoring legislation regarding the 340B Drug discount program. Issues pertaining to sequestration; H.R. 1934 Cancer Care Payment Reform Act. Issues related to pharmacy benefit managers.
- Issues pertaining to Medicare reimbursement. Issues pertaining to drug shortages, monitoring legislation regarding the 340B Drug discount program. Issues pertaining to sequestration; Issues related to pharmacy benefit managers. Drug Pricing legislation
- Issues pertaining to Medicare reimbursement. Issues pertaining to drug shortages, monitoring legislation regarding the 340B Drug discount program. Issues pertaining to sequestration; Issues related to pharmacy benefit managers. Drug Pricing legislation. CMMI Guardrails
- Issues pertaining to Medicare reimbursement. Issues pertaining to drug shortages, monitoring legislation regarding the 340B Drug discount program. Issues pertaining to sequestration; Issues related to pharmacy benefit managers. Drug Pricing legislation. Issues related to COVID-19 stimulus legislation.
- Issues pertaining to Medicare reimbursement. Issues pertaining to drug shortages, monitoring legislation regarding the 340B Drug discount program. Issues pertaining to sequestration; Issues related to pharmacy benefit managers. Drug Pricing legislation. CMMI Guardrails
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.